Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1

TL;DR

This study identifies two new compounds that inhibit the PARP-1 enzyme, which is important for DNA repair and a potential target for cancer treatment.

Contribution

The study introduces two novel chemical scaffolds with higher PARP-1 inhibitory activity than existing compounds.

Findings

Compound 57 showed the highest inhibitory activity in the compound library.

Compound 57 demonstrated five-fold higher PARP inhibitory activity than olaparib's core structure.

Compound 57 exhibited potential synergistic effects with temozolomide in DNA-damaging pathways.

Abstract

Poly(ADP-ribose) polymerases (PARP) are a family of enzymes that were proven to play an essential role in the initiation and activation of DNA repair processes in the case of DNA single-strand breaks. The inhibition of PARP enzymes might be a promising option for the treatment of several challenging types of cancers, including triple-negative breast cancer (TNBC) and non-small cell lung carcinoma (NSCLC). This study utilizes several techniques to screen the compound collection of the Leibniz Institute of Plant Biochemistry (IPB) to identify novel hPARP-1 inhibitors. First, an in silico pharmacophore-based docking study was conducted to virtually screen compounds with potential inhibitory effects. To evaluate these compounds in vitro, a cell-free enzyme assay was developed, optimized, and employed to identify hPARP-1 inhibitors, resulting in the discovery of two novel scaffolds represented by compounds 54 and 57, with the latter being the most active one from the compound library. Furthermore, fluorescence microscopy and synergism assays were performed to investigate the cellular and nuclear pathways of hPARP-1 inhibitor 57 and its potential synergistic effect with the DNA-damaging agent temozolomide. The findings suggest that the compound requires further lead optimization to enhance its ability to target the nuclear PARP enzyme effectively. Nonetheless, this new scaffold demonstrated a five-fold higher PARP inhibitory activity at the enzyme level compared to the core structure of olaparib (OLP), phthalazin-1(2H)-one.

Figures